Table 3.
(A) Prostate cancer (PC) recurrence (patient-group radical prostatectomy (RP)) location related to different PSA values. (B) PC recurrence (patient-group RT) location related to different PSA values.
| (A) Prostate cancer (PC) recurrence (patient-group radical prostatectomy (RP)) location related to different PSA values. | ||||||
| PSA (ng/mL) | 0.2–<0.5 | 0.5–<1.0 | 1.0–<2.0 | 2.0–<5.0 | ≥5.0 | Chi², p |
| Number (x/493) patient-group RP | 67 | 78 | 87 | 118 | 143 | |
| PET/CT positive | 27 | 48 | 61 | 99 | 135 | r = 0.413; p < 0.001 |
| Positivity rate | 40.3% | 61.5% | 70.1% | 83.9% | 94.4% | |
| Androgen deprivation therapy | 15 | 13 | 21 | 31 | 77 | r = 0.252; p < 0.001 |
| Regions: | ||||||
| Local recurrence | 6 | 14 | 19 | 29 | 41 | r = 0.149; p = 0.02 |
| Metastases | 22 | 39 | 49 | 80 | 123 | r = 0.365; p < 0.001 |
| Site of metastases: | r = 0.402; p < 0.001 | |||||
| Local metastases | 16 | 28 | 32 | 43 | 50 | |
| Distant metastases | 3 | 7 | 12 | 18 | 31 | |
| Local + distant metastases | 3 | 4 | 5 | 19 | 42 | |
| Number of metastases: | r = 0.397; p < 0.001 | |||||
| Single metastases | 14 | 14 | 23 | 25 | 29 | |
| Multiple metastases | 8 | 25 | 26 | 55 | 94 | |
| Lymph node metastases (LNM) | 19 | 30 | 38 | 61 | 97 | r = 0.266; p < 0.001 |
| Site of LNM: | r = 0.344; p < 0.001 | |||||
| Local LNM | 18 | 28 | 34 | 51 | 52 | |
| Distant LNM | 0 | 0 | 2 | 4 | 13 | |
| Local + distant LNM | 1 | 2 | 2 | 6 | 32 | |
| Bone metastases | 8 | 11 | 12 | 33 | 72 | r = 0.315; p < 0.001 |
| Visceral metastases | 1 | 1 | 2 | 5 | 12 | r = 0.128; p = 0.075 * |
| (B) PC recurrence (patient-group RT) location related to different PSA values. | ||||||
| PSA (ng/mL) | 2.0–<5.0 | ≥5.0 | Chi², p | |||
| Number (x/88) patient-group RT | 33 | 55 | ||||
| PET/CT positive | 29 | 51 | r = 0.08; p = 0.44 | |||
| Positivity rate | 87.9% | 92.7% | ||||
| Androgen deprivation therapy | 11 | 41 | r = 0.406; p = 0.001 | |||
| Regions: | ||||||
| Local recurrence | 21 | 29 | r = −0.107; p = 0.317 | |||
| Metastases | 14 | 37 | r = 0.244; p = 0.022 | |||
| Site of metastases: | r = 0.306; p = 0.011 | |||||
| Local metastases | 10 | 12 | ||||
| Distant metastases | 1 | 13 | ||||
| Local + distant metastases | 3 | 12 | ||||
| Number of metastases: | r = 0.289; p = 0.022 | |||||
| Single metastases | 6 | 7 | ||||
| Multiple metastases | 8 | 30 | ||||
| Lymph node metastases (LNM) | 12 | 23 | r = 0.054; n.s. | |||
| Site of LNM: | r = 0.076; n.s. | |||||
| Local LNM | 9 | 17 | ||||
| Distant LNM | 2 | 1 | ||||
| Local + distant LNM | 1 | 5 | ||||
| Bone metastases | 5 | 22 | r = −0.261; p = 0.014 | |||
| Visceral metastases | 2 | 1 | r = −0.113; n.s. | |||
* Fisher exact test. Abbreviations: PSA, prostate-specific-antigen; LNM, lymph node metastases; p < 0.05 is considered significant; r, Pearson correlation coefficient.